<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CPT</journal-id>
<journal-id journal-id-type="hwp">spcpt</journal-id>
<journal-id journal-id-type="nlm-ta">J Cardiovasc Pharmacol Ther</journal-id>
<journal-title>Journal of Cardiovascular Pharmacology and Therapeutics</journal-title>
<issn pub-type="ppub">1074-2484</issn>
<issn pub-type="epub">1940-4034</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1074248412458154</article-id>
<article-id pub-id-type="publisher-id">10.1177_1074248412458154</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Experimental Studies</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Iptakalim Ameliorates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>JunShan</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-1074248412458154">1</xref>
<xref ref-type="aff" rid="aff2-1074248412458154">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Long</surname>
<given-names>ChaoLiang</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1074248412458154">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cui</surname>
<given-names>WenYu</given-names>
</name>
<degrees>BS</degrees>
<xref ref-type="aff" rid="aff1-1074248412458154">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Hai</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1074248412458154">1</xref>
<xref ref-type="aff" rid="aff3-1074248412458154">3</xref>
<xref ref-type="corresp" rid="corresp1-1074248412458154"/>
</contrib>
</contrib-group>
<aff id="aff1-1074248412458154">
<label>1</label>Cardiovascular Drug Research Center, Institute of Health and Environmental Medicine, Academy of Military Medical Sciences, Beijing, China</aff>
<aff id="aff2-1074248412458154">
<label>2</label>Department of Pharmacy, The 309th Hospital of Chinese People's Liberation Army, Beijing, China</aff>
<aff id="aff3-1074248412458154">
<label>3</label>Thadweik Academy of Medicine, Beijing, China</aff>
<author-notes>
<corresp id="corresp1-1074248412458154">Hai Wang, Institute of Health and Environmental Medicine, Academy of Military Medical Sciences, Beijing 100850, the People’s Republic of China Email: <email>wh9588@yahoo.com.cn</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2013</year>
</pub-date>
<volume>18</volume>
<issue>1</issue>
<fpage>60</fpage>
<lpage>69</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec><title>Objectives:</title>
<p>We sought to investigate the experimental therapeutic effects and mechanisms of iptakalim, a new adenosine triphosphate (ATP)-sensitive potassium channel (K<sub>ATP</sub>) opener, on monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and right heart ventricle remodeling in rats.</p>
</sec>
<sec><title>Methods:</title>
<p>Rats were injected with a single dose (50 mg/kg, ip) of MCT and given iptakalim (1, 3, and 9 mg/kg·per d, orally [po]) or saline for 28 days. The hemodynamic and morphometric parameters were assessed. Tissue and plasma samples were collected for histological and molecular analysis.</p>
</sec>
<sec><title>Results:</title>
<p>Treatment with iptakalim at daily oral doses of 1, 3, and 9 mg/kg from the day of MCT injection attenuated the high right ventricle systolic pressure (RVSP) and the increased weight ratio of right ventricle (RV) to left ventricle (LV) plus septum (S) (RV/(LV+S)), decreased heart rate (HR) and decreased mean arterial pressure (MAP), inhibited the RV myocardial tissue cell apoptosis, and the RV myocardial cell B-type natriuretic peptide (BNP) protein expression. Iptakalim also decreased the serum levels of nitric oxide (NO), endothelin 1 (ET-1), BNP, and the levels of NO, ET-1, and tumor necrosis factor-alpha (TNF-α) in the lung tissue.</p>
</sec>
<sec><title>Conclusion:</title>
<p>These results indicate that iptakalim prevents MCT-induced PAH and RV remodeling and its mechanisms are related to inhibiting the pathological increases in NO, ET-1, BNP, and TNF-α, and Iptakalim may be a promising candidate for the treatment of PAH.</p>
</sec>
</abstract>
<kwd-group>
<kwd>ATP-sensitive potassium channel opener</kwd>
<kwd>iptakalim</kwd>
<kwd>monocrotaline</kwd>
<kwd>pulmonary arterial hypertension</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1074248412458154">
<title>Introduction</title>
<p>Pulmonary arterial hypertension (PAH) is a group of chronic and progressive diseases characterized by a sustained elevation of pulmonary vascular resistance, leading to right ventricular (RV) failure and premature death.<sup>
<xref ref-type="bibr" rid="bibr1-1074248412458154">1</xref>,<xref ref-type="bibr" rid="bibr2-1074248412458154">2</xref>
</sup> The exact pathogenesis of PAH is not fully understood, but recent evidence demonstrates that elevated pulmonary artery pressure is the result of vasoconstriction and structural remodeling of pulmonary vessels.<sup>
<xref ref-type="bibr" rid="bibr3-1074248412458154">3</xref>,<xref ref-type="bibr" rid="bibr4-1074248412458154">4</xref>
</sup> There are multiple and complex mechanisms involved in the progression of PAH, including proliferation of pulmonary arterial smooth muscle cells, endothelial dysfunction, and inflammation.<sup>
<xref ref-type="bibr" rid="bibr5-1074248412458154">5</xref>
<xref ref-type="bibr" rid="bibr6-1074248412458154"/>
<xref ref-type="bibr" rid="bibr7-1074248412458154"/>–<xref ref-type="bibr" rid="bibr8-1074248412458154">8</xref>
</sup>
</p>
<p>Iptakalim, 2,3-dimethyl-N-(1-methylethyl)-2-butanamine hydrochloride, is a new structural type of adenosine triphosphate–sensitive potassium channel (K<sub>ATP</sub>) opener, preferentially activating SUR2B/Kir6.1 subtype, without activation of SUR1/Kir6.2.<sup>
<xref ref-type="bibr" rid="bibr9-1074248412458154">9</xref>
<xref ref-type="bibr" rid="bibr10-1074248412458154"/>–<xref ref-type="bibr" rid="bibr11-1074248412458154">11</xref>
</sup> Its antihypertensive effects have been demonstrated in spontaneously hypertensive rats, renal hypertensive dogs, and patients.<sup>
<xref ref-type="bibr" rid="bibr12-1074248412458154">12</xref>
<xref ref-type="bibr" rid="bibr13-1074248412458154"/>–<xref ref-type="bibr" rid="bibr14-1074248412458154">14</xref>
</sup> Our previous studies showed that iptakalim inhibits the remodeling of the pulmonary artery in hypoxic pulmonary hypertensive rats and prevents progression of cardiac hypertrophy to failure induced by a pressure overload, via augmenting the release of nitric oxide (NO) and inhibiting the endothelin 1 (ET-1) system during endothelial dysfunction, thereby resulting in endothelial protection.<sup>
<xref ref-type="bibr" rid="bibr15-1074248412458154">15</xref>,<xref ref-type="bibr" rid="bibr16-1074248412458154">16</xref>
</sup> Iptakalim also inhibited the ET-1-induced proliferation of cultured human pulmonary arterial smooth muscle cells and rabbit pulmonary arterial smooth muscle cells, which suggested that iptakalim might be a promising candidate for the treatment of pulmonary arterial remodeling in PAH.<sup>
<xref ref-type="bibr" rid="bibr17-1074248412458154">17</xref>,<xref ref-type="bibr" rid="bibr18-1074248412458154">18</xref>
</sup>
</p>
<p>Chronic hypoxia and injection of monocrotaline (MCT) can establish PAH animal models, but the mechanism of the 2 models is different. Moreover, the performance of both models and the degree of damage are also different. Hypoxic PAH is usually only moderate and limited to medial hypertrophy with varying degrees of adventitial change, but may progress to extensive remodeling in some species. However, MCT-induced PAH is severe with endothelial degeneration or hyperplasia, hypertrophy of medial smooth muscle, and adventitial edema, which is used as a standard model for PAH.<sup>
<xref ref-type="bibr" rid="bibr19-1074248412458154">19</xref>
<xref ref-type="bibr" rid="bibr20-1074248412458154"/>–<xref ref-type="bibr" rid="bibr21-1074248412458154">21</xref>
</sup>
</p>
<p>Thus, we hypothesize that iptakalim might be effective in the treatment of PAH induced by MCT.</p>
</sec>
<sec id="section2-1074248412458154" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1074248412458154">
<title>Reagents</title>
<p>Iptakalim was synthesized by Thadweik Academy of Medicine (Beijing, China). Monocrotaline was purchased from Sigma-Aldrich (St Louis, Missouri). All other chemicals and materials were obtained from local commercial sources.</p>
</sec>
<sec id="section4-1074248412458154">
<title>Experimental Protocol</title>
<p>All procedures were performed in accordance with the protocol outlined in the Guide for the Care and Use of Laboratory Animals published by the US National Institute of Health (NIH publication no. 85-23, revised 1996) and approved by the local animal care and use committee. To assess preventive effects of iptakalim on MCT-induced PAH, adult male Wistar rats (180-220 g) were randomly divided into 5 groups (n = 10 per group): model group, 3 iptakalim treatment groups, and the control group. In the model group and the 3 iptakalim treatment groups, rats were given a single intraperitoneal injection of MCT (50 mg/kg), while the rats in the control group received an equal volume of physiological saline. The rats in the iptakalim treatment and model groups were further assigned at random to receive either iptakalim (1, 3, and 9 mg/kg per d, orally [po], respectively) or an equal volume of physiological saline from the day of the MCT injection up to the 28th day. Iptakalim was dissolved in saline and administered orally via a gastric tube. Iptakalim or vehicle was orally administered once a day in 2 mL/kg.</p>
</sec>
<sec id="section5-1074248412458154">
<title>Hemodynamics and Cardiac Remodeling Index</title>
<p>On day 28, all animals were weighed and anesthetized with a mixture of xylazine (5 mg/kg) and sodium pentobarbital (15 mg/kg, intraperitoneal injection). After stable anesthesia was obtained, 2 polyethylene catheters were inserted into the RV through the right jugular vein and the left carotid artery, respectively, for hemodynamic measurements.<sup>
<xref ref-type="bibr" rid="bibr6-1074248412458154">6</xref>,<xref ref-type="bibr" rid="bibr22-1074248412458154">22</xref>
</sup> Right ventricle systolic pressure (RVSP), systemic blood pressure, and heart rate (HR) were measured with a polygraph system (RM-6000, Nihon Kohden Kogyo Co, Ltd, Japan). Thereafter, blood samples were collected and animals were killed by exsanguination. The thoracic cavity was opened to expose the still beating heart. The heart and lung were rapidly removed, rinsed in ice-cold 0.9% NaCl solution, blotted, and then the heart was weighed. The heart weight (HW) index  was calculated by dividing HW by body weight (HW/BW). The left ventricles ([LVs] including interventricular septum, LV + S) and RV free walls were collected separately and weighed. The RV weight index (RV/(LV+S)) was calculated. The right lung was dissected into pieces, frozen in liquid nitrogen, and then stored at −80°C until biology assay.</p>
</sec>
<sec id="section6-1074248412458154">
<title>Histological Analysis</title>
<p>Right ventricle and left lung samples were immersion fixed in 10% buffered formalin and embedded in paraffin. Sections (4 μm) were cut and stained with hematoxylin and eosin. The structural changes in tissues were investigated using a light microscope. Intra-acinar vessels were analyzed to assess the distribution and the degree of muscularization according to the accompanying airway such as terminal bronchiole. The medial thickness and external diameter were recorded and assessed microscopically for the degree of arterial muscularization. The medial wall thickness was measured at 2 locations of each artery and was expressed as the summation of the 2 points of (medial thickness/external diameter)×100 (in percentage).<sup>23</sup>
</p>
</sec>
<sec id="section7-1074248412458154">
<title>Measurement of Serum NO Production, Plasma B-Type Natriuretic Peptide, and ET-1 Levels</title>
<p>Within 30 seconds after collection, heparinized blood was centrifuged for 10 minutes at 3000 rpm, and all samples were stored at −70°C until they were assayed. Because of its instability in physiological solutions, most of the NO is rapidly converted to nitrite (NO<sub>2</sub>
<sup>−</sup>) and further to nitrate (NO<sub>3</sub>
<sup>−</sup>). Serum levels of NO<sub>2</sub>
<sup>−</sup>/NO<sub>3</sub>
<sup>−</sup> were measured using NO Detection Kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China), according to the manufacturer’s instruction. Briefly, nitrate was converted into nitrite with aspergillus nitrite reductase, and the total nitrite was measured with the Griess reagent. The absorbance was determined at 540 nm with a spectrophotometer according to the instructions provided by the manufacturer. Both ET-1 and B-type natriuretic peptide (BNP) were measured using commercial radioimmunoassay kits (Eastern Asia Radioimmunity Research Institute, Beijing, China).</p>
</sec>
<sec id="section8-1074248412458154">
<title>Measurement of NO, ET-1, and Tumor Necrosis Factor-α in Lung Tissue</title>
<p>Freeze-stored lung was thawed, weighed, and homogenized in 0.8 mL of physiological saline per 200 mg of tissue. After homogenization on ice, the tissue samples were centrifuged (15 minutes, 4000 rpm at 4°C). The supernatant was used for measuring NO, ET-1, and tumor necrosis factor-α (TNF-α). The NO level in lungs was measured using NO Detection Kit (Nanjing Jiancheng Bioengineering Institute, Nanjing, China). The levels of ET-1 and TNF-α in lung tissues were measured using commercial radioimmunoassay kits (Eastern Asia Radioimmunity Research Institute).</p>
</sec>
<sec id="section9-1074248412458154">
<title>Assessment of the RV Myocardial Tissue Cell Apoptosis</title>
<p>In situ terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) was performed using an apoptosis detection kit (DeadEnd Colorimetric TUNEL System; Promega, Madison, Wisconsin). The RV myocardial tissues were immersion fixed in 10% formalin and embedded in paraffin. Paraffin sections of 4-μm-thick were cut and stained according to the manufacturer’s instructions. The number of TUNEL-positive cardiac myocyte nuclei was expressed as percentage of the total number of cardiac myocyte nuclei and called the apoptosis index. Five rat hearts in each group were randomly selected and 2 fields in each rat heart were analyzed (light microscopy, 400 magnifications).</p>
</sec>
<sec id="section10-1074248412458154">
<title>B-Type Natriuretic Peptide Protein Expression in the RV Myocardial Tissue</title>
<p>The RV myocardial tissues were immersion fixed in 10% formalin and embedded in paraffin. Paraffin sections of 4-μm-thick were cut, deparaffinized, and dehydrated. The streptavidin–peroxidase conjugate (SP) method was performed in sections stained with a primary polyclonal antibody (ab19645, abcam) to BNP. The degree of BNP expression was assessed by the mean optical density. Five rat hearts in each group were randomly selected and 2 fields in each rat heart were analyzed (light microscopy, ×400 magnifications).</p>
</sec>
<sec id="section11-1074248412458154">
<title>Statistical Analysis</title>
<p>Data are expressed as mean ± standard deviation (SD). Differences between groups were assessed by analysis of variance (ANOVA) and Student Newman–Keuls post hoc test for multiple comparisons. Statistical significance was accepted at <italic>P</italic> &lt; .05.</p>
</sec>
</sec>
<sec id="section12-1074248412458154">
<title>Results</title>
<sec id="section13-1074248412458154">
<title>Hemodynamic Effects of Iptakalim</title>
<p>As shown in <xref ref-type="table" rid="table1-1074248412458154">Table 1</xref>, on day 28 after MCT administration, RVSP, a reflex of PAH, in MCT-induced model group was elevated markedly compared with that in control group. However, HR and mean arterial pressure (MAP) in MCT-induced model group decreased significantly compared with the control group. Iptakalim at the daily oral doses of 1, 3, and 9 mg/kg for 28 days ameliorated the increase in RVSP and reduction in HR and MAP.</p>
<table-wrap id="table1-1074248412458154" position="float">
<label>Table 1.</label>
<caption>
<p>Effects of Iptakalim on RVSP, HR, and MAP in the Pulmonary Arterial Hypertensive Rats<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table1-1074248412458154" xlink:href="10.1177_1074248412458154-table1.tif"/>
<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>RVSP, mm Hg</th>
<th>HR, beats/min</th>
<th>MAP, mm Hg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>8</td>
<td>23.9 ± 2.6</td>
<td>450.6 ± 21.6</td>
<td>114.1 ± 3.3</td>
</tr>
<tr>
<td>Model</td>
<td>8</td>
<td>87.3 ± 14.3<sup>b</sup>
</td>
<td>324.6 ± 62.3<sup>b</sup>
</td>
<td>79.0 ± 21.3<sup>b</sup>
</td>
</tr>
<tr>
<td>MCT + Ipt 1 mg/kg</td>
<td>8</td>
<td>63.1 ± 19.8<sup>b,c</sup>
</td>
<td>439.9 ± 45.1<sup>c</sup>
</td>
<td>105.3 ± 10.0<sup>c,d</sup>
</td>
</tr>
<tr>
<td>MCT + Ipt 3 mg/kg</td>
<td>7</td>
<td>66.0 ± 20.6<sup>b,e</sup>
</td>
<td>414.0 ± 64.4<sup>e</sup>
</td>
<td>99.4 ± 8.6<sup>b,e</sup>
</td>
</tr>
<tr>
<td>MCT + Ipt 9 mg/kg</td>
<td>10</td>
<td>38.9 ± 16.0<sup>c,d</sup>
</td>
<td>460.9 ± 24.9<sup>c</sup>
</td>
<td>108.8 ± 6.9<sup>c</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1074248412458154">
<p>Abbreviations: RVSP, right ventricle systolic pressure; HR, heart rate; MAP, mean arterial blood pressure; MCT, monocrotaline; Ipt, iptakalim; SD, standard deviation.</p>
</fn>
<fn id="table-fn2-1074248412458154">
<p>
<sup>a</sup>Data are presented as means ± SD. </p>
</fn>
<fn id="table-fn3-1074248412458154">
<p>
<sup>b</sup>
<italic>P</italic>&lt; .01.</p>
</fn>
<fn id="table-fn4-1074248412458154">
<p>
<sup>c</sup>
<italic>P</italic>&lt; .01 versus control group.</p>
</fn>
<fn id="table-fn5-1074248412458154">
<p>
<sup>d</sup>
<italic>P</italic>&lt; .05.</p>
</fn>
<fn id="table-fn6-1074248412458154">
<p>
<sup>e</sup>
<italic>P</italic>&lt; .05 versus model group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section14-1074248412458154">
<title>Iptakalim Reduces the RV Hypertrophy Induced by MCT</title>
<p>As shown in <xref ref-type="table" rid="table2-1074248412458154">Table 2</xref>, on day 28 after MCT administration, HW, HW/BW, ratio of RV weight to LV plus septum (S) weight (RV/LV+S) in MCT-induced model group were elevated markedly compared with control group values; however, body weight (BW) in MCT-induced model group was decreased significantly compared with the control group. Iptakalim at the daily oral doses of 1, 3, and 9 mg/kg for 28 days ameliorated the increase in HW, HW/BW, and RV/LV+S. In addition, the body weight of the MCT-injected group did not differ from control with iptakalim treatment at the daily oral doses of 1, 3, and 9 mg/kg for 28 days.</p>
<table-wrap id="table2-1074248412458154" position="float">
<label>Table 2.</label>
<caption>
<p>Effects of Iptakalim on BW, HW, HW/BW, RV/(LV+S) in the Pulmonary Arterial Hypertensive Rats<sup>a</sup>
</p>
</caption>
<graphic alternate-form-of="table2-1074248412458154" xlink:href="10.1177_1074248412458154-table2.tif"/>
<table>
<thead>
<tr>
<th>Group</th>
<th>N</th>
<th>BW, g</th>
<th>HW, g</th>
<th>HW/BW, g/kg</th>
<th>RV/(LV+S), g/g</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>8</td>
<td>359.6 ± 19.1</td>
<td>0.96 ± 0.04</td>
<td>2.68 ± 0.06</td>
<td>0.22 ± 0.01</td>
</tr>
<tr>
<td>Model</td>
<td>8</td>
<td>278.0 ± 28.7<sup>b</sup>
</td>
<td>1.05 ± 0.04<sup>b</sup>
</td>
<td>3.80 ± 0.31<sup>b</sup>
</td>
<td>0.57 ± 0.03<sup>b</sup>
</td>
</tr>
<tr>
<td>MCT + I pt 1 mg/kg</td>
<td>8</td>
<td>293.5 ± 20.1<sup>b</sup>
</td>
<td>0.96 ± 0.08<sup>c</sup>
</td>
<td>3.29 ± 0.39<sup>b,d</sup>
</td>
<td>0.40 ± 0.08<sup>b,d</sup>
</td>
</tr>
<tr>
<td>MCT + Ipt 3 mg/kg</td>
<td>7</td>
<td>292.1 ± 17.4<sup>b</sup>
</td>
<td>1.00 ± 0.07</td>
<td>3.42 ± 0.31<sup>b</sup>
</td>
<td>0.44 ± 0.09<sup>b,d</sup>
</td>
</tr>
<tr>
<td>MCT + Ipt 9 mg/kg</td>
<td>10</td>
<td>283.8 ± 20.7<sup>b</sup>
</td>
<td>0.80 ± 0.05<sup>b,d</sup>
</td>
<td>2.82 ± 0.17<sup>c,e</sup>
</td>
<td>0.26 ± 0.02<sup>b,d</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-1074248412458154">
<p>Abbreviations: BW, body weight; HW, heart weight; HW/BW, ratio of HW to BW; RV, right ventricle; LV, left ventricle; S, septum weight; RV/(LV+S), ratio of RV to LV plus S; MCT, monocrotaline; Ipt, iptakalim; SD, standard deviation.</p>
</fn>
<fn id="table-fn8-1074248412458154">
<p>
<sup>a</sup>Data are presented as means ± SD.</p>
</fn>
<fn id="table-fn9-1074248412458154">
<p>
<sup>b</sup>
<italic>P</italic>&lt; .01.</p>
</fn>
<fn id="table-fn10-1074248412458154">
<p>
<sup>c</sup>
<italic>P</italic>&lt; .05 versus control group.</p>
</fn>
<fn id="table-fn11-1074248412458154">
<p>
<sup>d</sup>
<italic>P</italic>&lt; .01.</p>
</fn>
<fn id="table-fn12-1074248412458154">
<p>
<sup>e</sup>
<italic>P</italic>&lt; .05 versus model group.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-1074248412458154">
<title>Iptakalim Downregulates BNP Protein Expression in the RV Myocardial Cells</title>
<p>Because it was well recognized that BNP is a molecular marker of heart failure, we determined the effects of iptakalim on the expression of BNP in myocardial cells. As shown in <xref ref-type="fig" rid="fig1-1074248412458154">Figure 1</xref>, in the model group, the mean optical density of RV myocardial cell BNP protein expression dramatically increased when compared to control rats. These changes could be prevented significantly by treatment with iptakalim at the dose of 9 mg/kg per d for 4 weeks.</p>
<fig id="fig1-1074248412458154" position="float">
<label>Figure 1.</label>
<caption>
<p>Effect of iptakalim on B-type natriuretic peptide (BNP) protein expression in right ventricular tissues of pulmonary arterial hypertensive rats induced by monocrotaline. A, Representative figure of BNP protein expression in right ventricular tissues (×400). B, Statistic results of BNP protein expression in right ventricular tissues. 1 indicates control; 2, model; 3, iptakalim 1 mg/kg group; 4, iptakalim 3 mg/kg group; 5, iptakalim 9 mg/kg group. Data are expressed as mean ± standard deviation (SD), n = 10. **<italic>P</italic> &lt; .01 versus control group; <sup>#</sup>
<italic>P</italic> &lt; .05, <sup>##</sup>
<italic>P</italic> &lt; .01 versus model group.</p>
</caption>
<graphic xlink:href="10.1177_1074248412458154-fig1.tif"/>
</fig>
</sec>
<sec id="section16-1074248412458154">
<title>Iptakalim Inhibits Pathological Changes in Lung Tissues and RV Tissues</title>
<p>On day 28 after MCT administration, alveolar mononuclear cell infiltration was observed in lung tissue in areas of consolidation and fibroblasts. The wall of the pulmonary artery was thickened, and intimal smooth muscle cell disorder, hyperplasia, stenosis, and occlusion were also observed. The capillaries in lung tissues were expanded slightly and congested. The secretions of bronchia were increased, and necrotic epithelial cells, red blood cells, and edema fluid were found in the bronchial cavity (<xref ref-type="fig" rid="fig2-1074248412458154">Figure 2A</xref>). Histological examinations demonstrated that fibrosis of the heart occurred in the RV myocardium. The numbers of monocytes and lymphocytes increased in myocardial interstitial tissues. Scattered, small sheets of multiple foci of myocardial necrosis were also observed in the RV myocardium derived from the model group (<xref ref-type="fig" rid="fig2-1074248412458154">Figure 2B</xref>). The above mentioned pathological changes in lung tissues and RV tissues could be improved by treatment with iptakalim at the dose of 9 mg/kg per d for 4 weeks.</p>
<fig id="fig2-1074248412458154" position="float">
<label>Figure 2.</label>
<caption>
<p>Effects of iptakalim on histological changes of the lung tissues and the right ventricles in pulmonary arterial hypertensive rats induced by monocrotaline (hematoxylin and eosin stain, ×200). A, Representative figure of the lung tissues. B, Representative figure of right ventricles. C, The medial thickness of pulmonary arteries accompanying terminal bronchiole. 1 indicates control; 2, model; 3, iptakalim 1 mg/kg group; 4, iptakalim 3 mg/kg group; 5, iptakalim 9 mg/kg group. Data are expressed as mean ± standard deviation (SD), n = 5. *<italic>P</italic> &lt; .05, **<italic>P</italic> &lt; .01 versus control group; <sup>#</sup>
<italic>P</italic> &lt; .05 versus model group.</p>
</caption>
<graphic xlink:href="10.1177_1074248412458154-fig2.tif"/>
</fig>
<p>The MCT-treated rats had significantly increased medial wall thickness of muscular pulmonary arteries corresponding to terminal bronchioles compared with that of the control group. Iptakalim at the dose of 9 mg/kg per d treatment could reduce the MCT-induced increase in medial wall thickness significantly (<xref ref-type="fig" rid="fig2-1074248412458154">Figure 2C</xref>), suggesting that iptakalim at the high dose could attenuate MCT-induced pulmonary vascular remodeling.</p>
</sec>
<sec id="section17-1074248412458154">
<title>Iptakalim Attenuated the RV Myocardial Tissue Cell Apoptosis Induced by MCT</title>
<p>In the model group, the rate of the RV myocardial tissue cell apoptosis dramatically increased compared with the control rats (<xref ref-type="fig" rid="fig3-1074248412458154">Figure 3A</xref>). The cell apoptosis induced by MCT could be attenuated by treatment with iptakalim at the dose of 9 mg/kg per d for 4 weeks. But no obvious effects were observed in iptakalim 1 and 3 mg/kg per d treatment groups (<xref ref-type="fig" rid="fig3-1074248412458154">Figure 3B</xref>).</p>
<fig id="fig3-1074248412458154" position="float">
<label>Figure 3.</label>
<caption>
<p>Effects of iptakalim on myocardium cell apoptosis of the right ventricle in pulmonary arterial hypertensive rats induced by monocrotaline (terminal deoxynucleotidyl transferase dUTP nick end labeling [TUNEL] stain, ×400). A, Representative figure of myocardium cell apoptosis in right ventricular tissues. B, Statistic results of myocardium cell apoptosis in right ventricular tissues. 1 indicates control; 2, model; 3, iptakalim 1 mg/kg group; 4, iptakalim 3 mg/kg group; 5, iptakalim 9 mg/kg group. Data are expressed as mean ± standard deviation (SD), n = 10. **<italic>P</italic> &lt; .01 versus control group; <sup>##</sup>
<italic>P</italic> &lt; .01 versus model group.</p>
</caption>
<graphic xlink:href="10.1177_1074248412458154-fig3.tif"/>
</fig>
</sec>
<sec id="section18-1074248412458154">
<title>Iptakalim Downregulated Serum NO Production, Plasma BNP, and ET-1 Levels</title>
<p>We assessed the concentrations of serum NO, plasma BNP, and ET-1 in pulmonary arterial hypertensive rats and found they were increased at the end of 4 weeks after MCT administration. After treatment with iptakalim at the doses of 1, 3, and 9 mg/kg per d for 4 weeks, these parameters were reduced significantly (<xref ref-type="fig" rid="fig4-1074248412458154">Figure 4A</xref>-<xref ref-type="fig" rid="fig4-1074248412458154">C</xref>).</p>
<fig id="fig4-1074248412458154" position="float">
<label>Figure 4.</label>
<caption>
<p>Effects of iptakalim on serum levels of NO and plasma levels of BNP and ET-1 in monocrotaline-induced pulmonary arterial hypertensive rats. Data are expressed as mean ± SD, (A) n = 5-10; (B) n = 7-8; (C) n = 7-10. *<italic>P</italic> &lt; .05, **<italic>P</italic> &lt; .01 versus control group; <sup>#</sup>
<italic>P</italic> &lt; .05, <sup>##</sup>
<italic>P</italic> &lt; .01 versus model group. BNP indicates B-type natriuretic peptide; NO, nitric oxide; ET-1, endothelin 1; SD, standard deviation.</p>
</caption>
<graphic xlink:href="10.1177_1074248412458154-fig4.tif"/>
</fig>
</sec>
<sec id="section19-1074248412458154">
<title>Iptakalim Suppressed TNF-α, NO, and ET-1 Levels in Lung Tissues</title>
<p>Accumulating evidence indicated that TNF-α, NO, and ET-1 play important roles in lung injuries induced by MCT. As shown in <xref ref-type="fig" rid="fig5-1074248412458154">Figure 5</xref>, the lung TNF-α, NO, and ET-1 levels of the model group were increased significantly compared with those of the control group. These changes could be prevented by treatment with iptakalim at the dose of 1, 3, and 9 mg/kg per d for 4 weeks (<xref ref-type="fig" rid="fig5-1074248412458154">Figure 5A</xref>-<xref ref-type="fig" rid="fig5-1074248412458154">C</xref>).</p>
<fig id="fig5-1074248412458154" position="float">
<label>Figure 5.</label>
<caption>
<p>Effects of iptakalim on TNF-α, NO, and ET-1 levels in lung tissues of monocrotaline-induced pulmonary arterial hypertensive rats. Data are expressed as mean ± SD, (A) n = 8-10; (B) n = 5-10; (C) n = 8-10. *<italic>P</italic> &lt; .05, **<italic>P</italic> &lt; .01 versus control group; <sup>#</sup>
<italic>P</italic> &lt; .05, <sup>##</sup>
<italic>P</italic> &lt; .01 versus model group. NO indicates nitric oxide; ET-1, endothelin 1; SD, standard deviation; TNF-α, tumor necrosis factor-α.</p>
</caption>
<graphic xlink:href="10.1177_1074248412458154-fig5.tif"/>
</fig>
</sec>
</sec>
<sec id="section20-1074248412458154">
<title>Discussion</title>
<p>The MCT-induced rat has been widely used as an experimental model of PAH.<sup>
<xref ref-type="bibr" rid="bibr23-1074248412458154">23</xref>
</sup> Monocrotaline is a pyrrolizidine alkaloid found in the plant species <italic>Crotalaria spectabilis.</italic> When injected into rats with a single subcutaneous or intraperitoneal administration, MCT undergoes hepatic transformation from the action of the cytochrome P450 monooxygenase system in the liver to form the MCT pyrrole (MCTP), which injures vascular endothelium of pulmonary vessels within several hours, activates platelets within 1 week, and causes enhanced reactivity of pulmonary vessels to vasoconstrictive substances and muscular hypertrophy of the media of pulmonary vessels, and then leads to PAH and RV hypertrophy. This model mimics the clinical pathological and physiological conditions of idiopathic PAH (IPAH).<sup>
<xref ref-type="bibr" rid="bibr24-1074248412458154">24</xref>
</sup> The effects of iptakalim on pulmonary hypertension induced by hypoxia or ET-1 had been demonstrated in previous studies.<sup>
<xref ref-type="bibr" rid="bibr16-1074248412458154">16</xref>
<xref ref-type="bibr" rid="bibr17-1074248412458154"/>–<xref ref-type="bibr" rid="bibr18-1074248412458154">18</xref>
</sup> The K<sub>ATP</sub> subtypes found in the endothelium are mainly SUR2B/Kir6.1, which contribute to the maintenance of the resting membrane potential and regulate intracellular Ca<sup>2+</sup> levels that in turn affect the production and release of NO.<sup>
<xref ref-type="bibr" rid="bibr25-1074248412458154">25</xref>
</sup> Iptakalim, a newly selective K<sub>ATP</sub> opener, activates SUR2B/Kir6.1 preferentially and is a promising drug that could protect against endothelial dysfunction through activating K<sub>ATP</sub> channels in endothelial cells.<sup>
<xref ref-type="bibr" rid="bibr10-1074248412458154">10</xref>,<xref ref-type="bibr" rid="bibr11-1074248412458154">11</xref>,<xref ref-type="bibr" rid="bibr13-1074248412458154">13</xref>,<xref ref-type="bibr" rid="bibr15-1074248412458154">15</xref>,<xref ref-type="bibr" rid="bibr26-1074248412458154">26</xref>
</sup> The purpose of this study, therefore, was to investigate the potential effects of iptakalim on PAH and RV hypertrophy progression using the MCT-induced PAH rat model.</p>
<p>In the present study, on day 28 after MCT administration, the rat model of PAH was established successfully and RV remodeling was characterized by elevation of RVSP, HW, HW/BW, RV/(LV+S). The overexpression of myocardial cell BNP proteins in RV accompanied by elevation in plasma BNP level indicated that PAH progressed gradually to right heart failure, and confirms that BNP is a potentially important clinical biomarker of heart failure.<sup>
<xref ref-type="bibr" rid="bibr27-1074248412458154">27</xref>,<xref ref-type="bibr" rid="bibr28-1074248412458154">28</xref>
</sup> Elevation in the levels of lung TNF-α, NO, and serum NO were accompanied by decreases in MAP and HR in PAH rats induced by MCT with a feature of time dependence. The lung injuries were similar to those reported by Speyer et al and Markovic et al.<sup>
<xref ref-type="bibr" rid="bibr29-1074248412458154">29</xref>,<xref ref-type="bibr" rid="bibr30-1074248412458154">30</xref>
</sup>
</p>
<p>Iptakalim alleviated pulmonary artery pressure and reversed pulmonary arterial modeling in animal models induced by hypoxia or ET-1.<sup>
<xref ref-type="bibr" rid="bibr16-1074248412458154">16</xref>
<xref ref-type="bibr" rid="bibr17-1074248412458154"/>–<xref ref-type="bibr" rid="bibr18-1074248412458154">18</xref>
</sup> It restored the balance between the NO and ET signaling systems during endothelial dysfunction, by augmenting the release of NO and inhibiting the ET-1 system, resulting in endothelial protection.<sup>
<xref ref-type="bibr" rid="bibr26-1074248412458154">26</xref>
</sup> Its therapeutic effects on pulmonary hypertension might be related to its endothelial protective effects.</p>
<p>Our current data showed that all doses of iptakalim-treated PAH rats (1, 3, and 9 mg/kg per d) induced by MCT for 28 days suppressed the development of PAH, pulmonary vascular remodeling, and RV remodeling, which were accompanied by reduction in the levels of the lung TNF-α, NO, ET-1, blood BNP, NO, and ET-1 compared with the MCT-induced rats. Meanwhile, the mean optical density of RV myocardial cell BNP expression and the rate of the RV myocardial tissue cell apoptosis markedly decreased compared with the MCT-induced rats. Whereas, after treatment with iptakalim, the MAP and HR in model rats were increased significantly. However, in the iptakalim-treated animals, 3 mg/kg per d of the iptakalim-treated group showed mixed effects. There were no dose–response effect on RVSP, MAP, HR, HW, HW/BW, RV/(LV+S), and ET-1 levels in the plasma or lung tissues; the mechanism of iptakalim on PAH induced by MCT needs further experimental research. In addition, although the increases in pulmonary artery pressure and RV hypertrophy were comparable in the rat hypoxia and MCT model, the NO levels in plasma or lung tissues reveal major differences between the 2 models. The levels of TNF-α in lung tissues implied that inflammatory cytokines might play an important role in the development and progression of MCT-induced PAH.</p>
<p>In MCT-induced PAH rats, endothelial dysfunction was characterized by increased levels of NO and ET-1 both in lung tissues and in blood plasma. The change in NO was different from those reported for endothelial dysfunction induced by hyperuricemia or pressure overload.<sup>
<xref ref-type="bibr" rid="bibr10-1074248412458154">10</xref>,<xref ref-type="bibr" rid="bibr11-1074248412458154">11</xref>,<xref ref-type="bibr" rid="bibr15-1074248412458154">15</xref>
</sup> In these 2 animal models, the serum levels of NO were decreased significantly, which could be reversed by iptakalim treatment. But in MCT-indiced PAH rats, the MCTP mediates its effects through interaction with receptors on the surface of a variety of host cells. These interactions result in the production and release of numerous biochemical mediators including inflammatory cytokines, NO, and toxic oxygen radicals.<sup>
<xref ref-type="bibr" rid="bibr31-1074248412458154">31</xref>
</sup> Inflammatory cytokines, such as TNF-α and interleukin 1 (IL-1), induced the overexpression of inducible NO synthase (iNOS) in vascular endothelial cells and myocardial cells, which increased the NO concentration levels in circulating blood multiple times higher than the normal physiological levels. Thus, the soluble guanylate cyclase (sGC) of vascular smooth muscle cells was activated, leading to the production of large amounts of cyclic guanosine monophosphate (cGMP), which caused the relaxation of vascular smooth muscle and decreased the systemic circulation blood pressure.<sup>
<xref ref-type="bibr" rid="bibr32-1074248412458154">32</xref>
<xref ref-type="bibr" rid="bibr33-1074248412458154"/>–<xref ref-type="bibr" rid="bibr34-1074248412458154">34</xref>
</sup> The excessive NO produced combined with superoxide anion (O<sub>2</sub>
<sup>-</sup>) to produce peroxy nitrite (ONOO<sup>-</sup>). ONOO<sup>-</sup> could enhance cardiovascular endothelial cell and cardiac cell inflammatory damage and mediate histiocyte apoptosis, resulting in RV remodeling, pulmonary vascular remodeling, and PAH.<sup>
<xref ref-type="bibr" rid="bibr35-1074248412458154">35</xref>
<xref ref-type="bibr" rid="bibr36-1074248412458154"/>
<xref ref-type="bibr" rid="bibr37-1074248412458154"/>
<xref ref-type="bibr" rid="bibr38-1074248412458154"/>
<xref ref-type="bibr" rid="bibr39-1074248412458154"/>
<xref ref-type="bibr" rid="bibr40-1074248412458154"/>
<xref ref-type="bibr" rid="bibr41-1074248412458154"/>
<xref ref-type="bibr" rid="bibr42-1074248412458154"/>
<xref ref-type="bibr" rid="bibr43-1074248412458154"/>–<xref ref-type="bibr" rid="bibr44-1074248412458154">44</xref>
</sup> In this PAH model, iptakalim treatment for 4 weeks not only decreased the high RVSP that is a reflex of PAH, but also reversed the pathological increase in levels of NO and ET-1.</p>
<p>In conclusion, our data suggests that MCTP, a dehydromonocrotaline metabolite, activates monocytes/macrophages to produce cytokines such as TNF-α and then induces excessive release of NO which in turn depresses cardiac function and causes injury of vascular endothelial cells directly and/or indirectly. All of these changes induce PAH, low systemic blood pressure, and HR. Iptakalim, a new K<sub>ATP</sub> channel opener, prevented MCT-induced PAH, reduced RV remodeling, increased the MAP and HR, inhibited pathological NO release, ET-1 secretion, and TNF-α release in MCT animals. Results of this study suggest that iptakalim might be a promising candidate for the treatment of PAH.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn1-1074248412458154">
<label>Authors' Note</label>
<p>JunShan Li, ChaoLiang Long, WenYu Cui, and Hai Wang designed the research; JunShan Li performed the research; JunShan Li and ChaoLiang Long analyzed data; JunShan Li and ChaoLiang Long wrote the paper.</p>
</fn>
<fn fn-type="conflict" id="fn2-1074248412458154">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-1074248412458154">
<label>Funding</label>
<p>The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by grants from National New Drug Research and Development Key Project (2010ZX09401-307, 2008ZXJ09004-018 and 2009ZX09301-002).</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1074248412458154">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schannwell</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Steiner</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Strauer</surname>
<given-names>BE</given-names>
</name>
</person-group>. <article-title>Diagnostics in pulmonary hypertension</article-title>. <source>J Physiol Pharmacol</source>. <year>2007</year>;<volume>58</volume>(<issue>suppl 5 pt 2</issue>):<fpage>591</fpage>–<lpage>602</lpage>.</citation>
</ref>
<ref id="bibr2-1074248412458154">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galiè</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hoeper</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Humbert</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>(<issue>20</issue>):<fpage>2493</fpage>–<lpage>2537</lpage>.</citation>
</ref>
<ref id="bibr3-1074248412458154">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Galiè</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Manes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Negro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Palazzini</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bacchi-Reggiani</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Branzi</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>A meta-analysis of randomized controlled trials in pulmonary arterial hypertension</article-title>. <source>Eur Heart J</source>. <year>2009</year>;<volume>30</volume>(<issue>4</issue>):<fpage>394</fpage>–<lpage>403</lpage>.</citation>
</ref>
<ref id="bibr4-1074248412458154">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crosswhite</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Z</given-names>
</name>
</person-group>. <article-title>Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension</article-title>. <source>J Hypertens</source>. <year>2010</year>;<volume>28</volume>(<issue>2</issue>):<fpage>201</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr5-1074248412458154">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Böhm</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pernow</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The importance of endothelin-1 for vascular dysfunction in cardiovascular disease</article-title>. <source>Cardiovasc Res</source>. <year>2007</year>;<volume>76</volume>(<issue>1</issue>):<fpage>8</fpage>–<lpage>18</lpage>.</citation>
</ref>
<ref id="bibr6-1074248412458154">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Csiszar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Labinskyy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Resveratrol prevents monocrotaline-induced pulmonary hypertension in rats</article-title>. <source>Hypertension</source>. <year>2009</year>;<volume>54</volume>(<issue>3</issue>):<fpage>668</fpage>–<lpage>675</lpage>.</citation>
</ref>
<ref id="bibr7-1074248412458154">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hironaka</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hongo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats</article-title>. <source>Cardiovasc Res</source>. <year>2003</year>;<volume>60</volume>(<issue>3</issue>):<fpage>692</fpage>–<lpage>699</lpage>.</citation>
</ref>
<ref id="bibr8-1074248412458154">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Firth</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>JX</given-names>
</name>
</person-group>. <article-title>Idiopathic pulmonary arterial hypertension</article-title>. <source>Dis Model Mech</source>. <year>2010</year>;<volume>3</volume>(<issue>5-6</issue>):<fpage>268</fpage>–<lpage>273</lpage>.</citation>
</ref>
<ref id="bibr9-1074248412458154">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YL</given-names>
</name>
</person-group>. <article-title>ATP-sensitive potassium channel openers and 2,3-dimethyl-2-butylamine derivatives</article-title>. <source>Curr Med Chem</source>. <year>2007</year>;<volume>14</volume>(<issue>2</issue>):<fpage>133</fpage>–<lpage>155</lpage>.</citation>
</ref>
<ref id="bibr10-1074248412458154">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Long</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>XC</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>ZY</given-names>
</name>
<etal/>
</person-group>. <article-title>Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia</article-title>. <source>J Hypertens</source>. <year>2008</year>;<volume>26</volume>(<issue>12</issue>):<fpage>2326</fpage>–<lpage>2338</lpage>.</citation>
</ref>
<ref id="bibr11-1074248412458154">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Activation of SUR2B/Kir6.1 subtype of adenosine triphosphate–sensitive potassium channel improves pressure overload induced cardiac remodeling via protecting endothelial function</article-title>. <source>J Cardiovasc Pharmacol</source>. <year>2010</year>;<volume>56</volume>(<issue>4</issue>):<fpage>345</fpage>–<lpage>353</lpage>.</citation>
</ref>
<ref id="bibr12-1074248412458154">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>YL</given-names>
</name>
</person-group>. <article-title>A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension</article-title>. <source>J Pharmacol Exp Ther</source>. <year>2005</year>;<volume>312</volume>(<issue>3</issue>):<fpage>1326</fpage>–<lpage>1333</lpage>.</citation>
</ref>
<ref id="bibr13-1074248412458154">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Targeting hypertension with a new ATP sensitive potassium channel opener iptakalim</article-title>. <source>J Cardiovasc Pharmacol</source>. <year>2010</year>;<volume>56</volume>(<issue>3</issue>):<fpage>215</fpage>–<lpage>228</lpage>.</citation>
</ref>
<ref id="bibr14-1074248412458154">
<label>14</label>
<citation citation-type="journal">
<collab collab-type="author">Hai Wang</collab>. <article-title>Pharmacological characteristics of the novel antihypertensive drug, iptakalim hydrochloride, and its molecular mechanisms</article-title>. <source>Drug Dev Res</source>. <year>2003</year>;<volume>58</volume>:<fpage>65</fpage>–<lpage>68</lpage>.</citation>
</ref>
<ref id="bibr15-1074248412458154">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>K<sub>ATP</sub> activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function</article-title>. <source>Cardiovasc Res</source>. <year>2009</year>;<volume>83</volume>(<issue>3</issue>):<fpage>444</fpage>–<lpage>456</lpage>.</citation>
</ref>
<ref id="bibr16-1074248412458154">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Effects of iptakalim hydrochloride, a novel K<sub>ATP</sub> channel opener, on pulmonary vascular remodeling in hypoxic rats</article-title>. <source>Life Sci</source>. <year>2004</year>;<volume>75</volume>(<issue>17</issue>):<fpage>2065</fpage>–<lpage>2076</lpage>.</citation>
</ref>
<ref id="bibr17-1074248412458154">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>G.</given-names>
</name>
</person-group> <article-title>Anti-proliferating effect of iptakalim, a novel K<sub>ATP</sub> channel opener, in cultured rabbit pulmonary arterial smooth muscle cells</article-title>. <source>Eur J Pharmacol</source>. <year>2005</year>;<volume>511</volume>(<issue>2-3</issue>):<fpage>81</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr18-1074248412458154">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Iptakalim inhibited endothelin-1-induced proliferation of human pulmonary arterial smooth muscle cells through the activation of K<sub>ATP</sub> channel</article-title>. <source>Vasc Pharmacol</source>. <year>2008</year>;<volume>48</volume>(<issue>2-3</issue>):<fpage>92</fpage>–<lpage>99</lpage>.</citation>
</ref>
<ref id="bibr19-1074248412458154">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stenmark</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Meyrick</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Galie</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mooi</surname>
<given-names>WJ</given-names>
</name>
<name>
<surname>McMurtry</surname>
<given-names>IF</given-names>
</name>
</person-group>. <article-title>Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure</article-title>. <source>Am J Physiol Lung Cell Mol Physiol</source>. <year>2009</year>;<volume>297</volume>(<issue>6</issue>):<fpage>L1013</fpage>–<lpage>L1032</lpage>.</citation>
</ref>
<ref id="bibr20-1074248412458154">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naeije</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dewachter</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Animal models of pulmonary arterial hypertension</article-title>. <source>Rev Mal Respir</source>. <year>2007</year>;<volume>24</volume>(<issue>4 pt 1</issue>):<fpage>481</fpage>–<lpage>496</lpage>.</citation>
</ref>
<ref id="bibr21-1074248412458154">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dorfmüller</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Perros</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Balabanian</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Humbert</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Inflammation in pulmonary arterial hypertension</article-title>. <source>Eur Respir J</source>. <year>2003</year>;<volume>22</volume>(<issue>2</issue>):<fpage>358</fpage>–<lpage>363</lpage>.</citation>
</ref>
<ref id="bibr22-1074248412458154">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prié</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Dupuis</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Endothelin A receptor blockade improves nitric oxide-mediated vasodilation in monocrotaline-induced pulmonary hypertension</article-title>. <source>Circulation</source>. <year>1998</year>;<volume>97</volume>(<issue>21</issue>):<fpage>2169</fpage>–<lpage>2174</lpage>.</citation>
</ref>
<ref id="bibr23-1074248412458154">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Homma</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Morio</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension</article-title>. <source>Respiration</source>. <year>2006</year>;<volume>73</volume>(<issue>1</issue>):<fpage>105</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr24-1074248412458154">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawamura</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kato</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Beardsworth</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats</article-title>. <source>J Pharmacol Sci</source>. <year>2009</year>;<volume>111</volume>(<issue>3</issue>):<fpage>235</fpage>–<lpage>243</lpage>.</citation>
</ref>
<ref id="bibr25-1074248412458154">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minamino</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hori</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Protecting endothelial function: a novel therapeutic target of ATP-sensitive potassium channel openers</article-title>. <source>Cardiovasc Res</source>. <year>2007</year>;<volume>73</volume>(<issue>3</issue>):<fpage>448</fpage>–<lpage>449</lpage>.</citation>
</ref>
<ref id="bibr26-1074248412458154">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells</article-title>. <source>Cardiovasc Res</source>. <year>2007</year>;<volume>73</volume>(<issue>3</issue>):<fpage>497</fpage>–<lpage>503</lpage>.</citation>
</ref>
<ref id="bibr27-1074248412458154">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daniels</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>Maisel</surname>
<given-names>AS</given-names>
</name>
</person-group>. <article-title>Natriuretic peptides</article-title>. <source>J Am Coll Cardiol</source>. <year>2007</year>;<volume>50</volume>(<issue>25</issue>):<fpage>2357</fpage>–<lpage>2368</lpage>.</citation>
</ref>
<ref id="bibr28-1074248412458154">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Woodard</surname>
<given-names>Ge</given-names>
</name>
<name>
<surname>Rosado</surname>
<given-names>JA.</given-names>
</name>
</person-group> <article-title>Recent advances in natriuretic peptide research</article-title>. <source>J Cell Mol Med</source>. <year>2007</year>;<volume>11</volume>(<issue>6</issue>):<fpage>1263</fpage>–<lpage>1271</lpage>.</citation>
</ref>
<ref id="bibr29-1074248412458154">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Speyer</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Neff</surname>
<given-names>TA</given-names>
</name>
<name>
<surname>Warner</surname>
<given-names>RL</given-names>
</name>
<etal/>
</person-group>. <article-title>Regulatory effects of iNOS on acute lung inflammatory responses in mice</article-title>. <source>Am J Pathol</source>. <year>2003</year>;<volume>163</volume>(<issue>6</issue>):<fpage>2319</fpage>–<lpage>2328</lpage>.</citation>
</ref>
<ref id="bibr30-1074248412458154">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Markovic</surname>
<given-names>N</given-names>
</name>
<name>
<surname>McCaig</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Stephen</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Mediators released from LPS-challenged lungs induce inflammatory responses in liver vascular endothelial cells and neutrophilic leukocytes</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source>. <year>2009</year>;<volume>297</volume>(<issue>6</issue>):<fpage>G1066</fpage>–<lpage>G1076</lpage>.</citation>
</ref>
<ref id="bibr31-1074248412458154">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guignabert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Raffestin</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Benferhat</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>111</volume>(<issue>21</issue>):<fpage>2812</fpage>–<lpage>2819</lpage>.</citation>
</ref>
<ref id="bibr32-1074248412458154">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drexler</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Nitric oxide synthases in the failing human heart: a doubled-edged sword?</article-title> <source>Circulation</source>. <year>1999</year>;<volume>99</volume>(<issue>23</issue>):<fpage>2972</fpage>–<lpage>2975</lpage>.</citation>
</ref>
<ref id="bibr33-1074248412458154">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Radomski</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moncada</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Porcine ventricular endocardial cells in culture express the inducible form of nitric oxide synthase</article-title>. <source>Br J Pharmacol</source>. <year>1993</year>;<volume>108</volume>(<issue>4</issue>):<fpage>1107</fpage>–<lpage>1110</lpage>.</citation>
</ref>
<ref id="bibr34-1074248412458154">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mendonca</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats</article-title>. <source>J Clin Invest</source>. <year>1997</year>;<volume>100</volume>(<issue>2</issue>):<fpage>439</fpage>–<lpage>448</lpage>.</citation>
</ref>
<ref id="bibr35-1074248412458154">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Campian</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Verberne</surname>
<given-names>HJ</given-names>
</name>
<name>
<surname>Hardziyenka</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Serial noninvasive assessment of apoptosis during right ventricular disease progression in rats</article-title>. <source>J Nucl Med</source>. <year>2009</year>;<volume>50</volume>(<issue>8</issue>):<fpage>1371</fpage>–<lpage>1377</lpage>.</citation>
</ref>
<ref id="bibr36-1074248412458154">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ing</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Zang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dzau</surname>
<given-names>VJ</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Bishopric</surname>
<given-names>NH</given-names>
</name>
</person-group>. <article-title>Modulation of cytokine-induced cardiac myocyte apoptosis by nitric oxide, Bak, and Bcl-x</article-title>. <source>Circ Res</source>. <year>1999</year>;<volume>84</volume>(<issue>1</issue>):<fpage>21</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr37-1074248412458154">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Eleuteri</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Magno</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Gnemmi</surname>
<given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of oxidative and nitrosative stress biomarkers in chronic heart failure</article-title>. <source>Front Biosci</source>. <year>2009</year>;<volume>14</volume>:<fpage>2230</fpage>–<lpage>2237</lpage>.</citation>
</ref>
<ref id="bibr38-1074248412458154">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jurasz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Courtman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Babaie</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>DJ</given-names>
</name>
</person-group>. <article-title>Role of apoptosis in pulmonary hypertension: from experimental models to clinical trials</article-title>. <source>Pharmacol Ther</source>. <year>2010</year>;<volume>126</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr39-1074248412458154">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hassoun</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Mouthon</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Barberà</surname>
<given-names>JA</given-names>
</name>
<etal/>
</person-group>. <article-title>Inflammation, growth factors, and pulmonary vascular remodeling</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>1 suppl</issue>):<fpage>S10</fpage>–<lpage>S19</lpage>.</citation>
</ref>
<ref id="bibr40-1074248412458154">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>HM</given-names>
</name>
<etal/>
</person-group>. <article-title>L-arginine enhances nitrative stress and exacerbates tumor necrosis factor-alpha toxicity to human endothelial cells in culture: prevention by propofol</article-title>. <source>J Cardiovasc Pharmacol</source>. <year>2010</year>;<volume>55</volume>(<issue>4</issue>):<fpage>358</fpage>–<lpage>367</lpage>.</citation>
</ref>
<ref id="bibr41-1074248412458154">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankov</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kantores</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Peroxynitrite mediates right-ventricular dysfunction in nitric oxide-exposed juvenile rats</article-title>. <source>Free Radic Biol Med</source>. <year>2010</year>;<volume>49</volume>(<issue>9</issue>):<fpage>1453</fpage>–<lpage>1467</lpage>.</citation>
</ref>
<ref id="bibr42-1074248412458154">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Touyz</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Schiffrin</surname>
<given-names>EL</given-names>
</name>
</person-group>. <article-title>Reactive oxygen species in vascular biology: implications in hypertension</article-title>. <source>Histochem Cell Biol</source>. <year>2004</year>;<volume>122</volume>(<issue>4</issue>):<fpage>339</fpage>–<lpage>352</lpage>.</citation>
</ref>
<ref id="bibr43-1074248412458154">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>NADPH oxidase and endothelial cell function</article-title>. <source>Clin Sci (Lond)</source>. <year>2005</year>;<volume>109</volume>(<issue>3</issue>):<fpage>217</fpage>–<lpage>226</lpage>.</citation>
</ref>
<ref id="bibr44-1074248412458154">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Redout</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Zuidwijk</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Right-ventricular failure is associated with increased mitochondrial complex II activity and production of reactive oxygen species</article-title>. <source>Cardiovasc Res</source>. <year>2007</year>;<volume>75</volume>(<issue>4</issue>):<fpage>770</fpage>–<lpage>781</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>